FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998052180> ?p ?o ?g. }

• W1998052180 endingPage "2449" @default.
• W1998052180 startingPage "2443" @default.
• W1998052180 abstract "Epidemiological and preclinical studies suggest that diets that are rich in n-3 polyunsaturated fatty acids (PUFAs) and selenium (Se) reduce the risk of colon cancer. Studies conducted in our laboratory have indicated that synthetic organoselenium 1,4-phenylene bis(methylene) selenocyanate ( p -XSC) is less toxic and more effective than inorganic Se and selenomethionine, the major Se compound in natural selenium yeast. Through cDNA microarray analysis, we have demonstrated earlier that the n-3 PUFA docosahexaenoic acid (DHA), modulated more than one signaling pathway by altering several genes involved in colon cancer growth. There is increasing interest in the use of combinations of low doses of chemopreventive agents that differ in their specific modes of action as this approach can minimize toxicity and increase efficacy in model assays. In the present study we assessed the efficacy of DHA and p -XSC individually and in combination at low doses in CaCo-2 colon cancer cells, using cell growth inhibition and apoptosis as measures of chemopreventive efficacy. On the basis of western blot and RT–PCR analysis, we also determined the effects of DHA and p -XSC on the levels of expression of cyclooxygenase-2, inducible nitric oxide synthase, cyclin D1, β-catenin and nuclear factor κB, all of which presumably participate in colon carcinogenesis. A 48 h incubation of CaCo-2 cells with 5 µM each DHA or p -XSC induced cell growth inhibition and apoptosis and altered the expression of the above molecular parameters. Interestingly, the modulation of these cellular and molecular parameters was more pronounced in cells treated with low doses of DHA and p -XSC (2.5 µM each) in combination than in cells treated with these agents individually at higher concentrations (5.0 µM each). These findings are viewed as highly significant since they will provide the basis for the development of combinations of low dose regimens of DHA and p -XSC in preclinical models against colon carcinogenesis and, ultimately, in human clinical trials." @default.
• W1998052180 created "2016-06-24" @default.
• W1998052180 creator A5004691943 @default.
• W1998052180 creator A5028241568 @default.
• W1998052180 creator A5056238262 @default.
• W1998052180 creator A5064185156 @default.
• W1998052180 creator A5082424937 @default.
• W1998052180 date "2004-12-01" @default.
• W1998052180 modified "2023-10-17" @default.
• W1998052180 title "Effects of a combination of docosahexaenoic acid and 1,4-phenylene bis(methylene) selenocyanate on cyclooxygenase 2, inducible nitric oxide synthase and β-catenin pathways in colon cancer cells" @default.
• W1998052180 cites W114912186 @default.
• W1998052180 cites W1904486154 @default.
• W1998052180 cites W1919721665 @default.
• W1998052180 cites W1964595762 @default.
• W1998052180 cites W1970347121 @default.
• W1998052180 cites W1989077543 @default.
• W1998052180 cites W2020242649 @default.
• W1998052180 cites W2020510569 @default.
• W1998052180 cites W2032307016 @default.
• W1998052180 cites W2034194860 @default.
• W1998052180 cites W2043629265 @default.
• W1998052180 cites W2056935575 @default.
• W1998052180 cites W2061385217 @default.
• W1998052180 cites W2062913179 @default.
• W1998052180 cites W2087675671 @default.
• W1998052180 cites W2102694695 @default.
• W1998052180 cites W2103253489 @default.
• W1998052180 cites W2104627052 @default.
• W1998052180 cites W2104944130 @default.
• W1998052180 cites W2109694492 @default.
• W1998052180 cites W2120545807 @default.
• W1998052180 cites W2127218675 @default.
• W1998052180 cites W2137658327 @default.
• W1998052180 cites W2139318333 @default.
• W1998052180 cites W2143793120 @default.
• W1998052180 cites W2144300167 @default.
• W1998052180 cites W2146559835 @default.
• W1998052180 cites W2150484958 @default.
• W1998052180 cites W2162216689 @default.
• W1998052180 cites W4295115868 @default.
• W1998052180 doi "https://doi.org/10.1093/carcin/bgh252" @default.
• W1998052180 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15297372" @default.
• W1998052180 hasPublicationYear "2004" @default.
• W1998052180 type Work @default.
• W1998052180 sameAs 1998052180 @default.
• W1998052180 citedByCount "78" @default.
• W1998052180 countsByYear W19980521802012 @default.
• W1998052180 countsByYear W19980521802013 @default.
• W1998052180 countsByYear W19980521802014 @default.
• W1998052180 countsByYear W19980521802015 @default.
• W1998052180 countsByYear W19980521802016 @default.
• W1998052180 countsByYear W19980521802017 @default.
• W1998052180 countsByYear W19980521802018 @default.
• W1998052180 countsByYear W19980521802019 @default.
• W1998052180 countsByYear W19980521802020 @default.
• W1998052180 countsByYear W19980521802021 @default.
• W1998052180 countsByYear W19980521802022 @default.
• W1998052180 countsByYear W19980521802023 @default.
• W1998052180 crossrefType "journal-article" @default.
• W1998052180 hasAuthorship W1998052180A5004691943 @default.
• W1998052180 hasAuthorship W1998052180A5028241568 @default.
• W1998052180 hasAuthorship W1998052180A5056238262 @default.
• W1998052180 hasAuthorship W1998052180A5064185156 @default.
• W1998052180 hasAuthorship W1998052180A5082424937 @default.
• W1998052180 hasBestOaLocation W19980521801 @default.
• W1998052180 hasConcept C181199279 @default.
• W1998052180 hasConcept C185592680 @default.
• W1998052180 hasConcept C190283241 @default.
• W1998052180 hasConcept C19038510 @default.
• W1998052180 hasConcept C2777171753 @default.
• W1998052180 hasConcept C2777622882 @default.
• W1998052180 hasConcept C502942594 @default.
• W1998052180 hasConcept C543025807 @default.
• W1998052180 hasConcept C55493867 @default.
• W1998052180 hasConcept C62112901 @default.
• W1998052180 hasConcept C86803240 @default.
• W1998052180 hasConcept C98274493 @default.
• W1998052180 hasConceptScore W1998052180C181199279 @default.
• W1998052180 hasConceptScore W1998052180C185592680 @default.
• W1998052180 hasConceptScore W1998052180C190283241 @default.
• W1998052180 hasConceptScore W1998052180C19038510 @default.
• W1998052180 hasConceptScore W1998052180C2777171753 @default.
• W1998052180 hasConceptScore W1998052180C2777622882 @default.
• W1998052180 hasConceptScore W1998052180C502942594 @default.
• W1998052180 hasConceptScore W1998052180C543025807 @default.
• W1998052180 hasConceptScore W1998052180C55493867 @default.
• W1998052180 hasConceptScore W1998052180C62112901 @default.
• W1998052180 hasConceptScore W1998052180C86803240 @default.
• W1998052180 hasConceptScore W1998052180C98274493 @default.
• W1998052180 hasIssue "12" @default.
• W1998052180 hasLocation W19980521801 @default.
• W1998052180 hasLocation W19980521802 @default.
• W1998052180 hasOpenAccess W1998052180 @default.
• W1998052180 hasPrimaryLocation W19980521801 @default.
• W1998052180 hasRelatedWork W1525185987 @default.
• W1998052180 hasRelatedWork W1986450487 @default.
• W1998052180 hasRelatedWork W1994494562 @default.
• W1998052180 hasRelatedWork W2004534398 @default.

• next